POWERFUL NEWS:

MMRF BLOG


 December 11, 2013

MMRF Newsflash from ASH 2013 - Volume 5

Welcome to the final day of MMRF onsite coverage from the 2013 American Society of Hematology (ASH) Annual meeting.

The abstracts focused on first-line therapy and relapsed/refractory treatment, including some featuring compounds in very early development for multiple myeloma. Additionally, an initial interim analysis of the MMRF CoMMpassSM Study was presented. To hear perspectives from myeloma experts on the data from ASH, please watch the MMRF webcast with Drs. Ola Landgren and Maria-Victoria Mateos. Watch now! Learn more about the latest advances in myeloma research and treatments by participating in the MMRF Highlights From the 2013 ASH Annual Meeting Webcast/Teleconference scheduled for December 18th at 1:00PM ET. Register now!

Upfront Therapy

Dr. Shaji Kumar from the Mayo Clinic presented data from a Phase I/II trial on ixazomib (aka MLN9708), a new oral proteasome inhibitor, combined with Revlimid and dexamethasone in previously untreated myeloma patients. The overall response rate in this trial was 100%, with 23% complete responses (CR). Based on the positive results, a Phase III trial is underway and enrolling. Call the MMRF Patient Support Center at 1-866-603-6628 to find out more.

Relapsed/Refractory Disease

Dr. Antonio Palumbo from the University of Torino in Italy presented results on a trial evaluating, cyclophosphamide, and prednisone in relapsed/refractory patients followed by Pomalyst and dexamethasone maintenance therapy. This trial is ongoing. At the time of this presentation, 55 patients had received at least 1 treatment cycle. Patients with relapsed/refractory disease who had received at least 1 to 3 prior therapies were eligible to participate. The overall response rate was 51%, with 6% achieving a CR and 24% a VGPR.

Dr. Noopur Raje from Mass General Hospital presented data for a Phase I trial of the new anti-BAFF antibody tabalumab, combined with Velcade and dexamethasone. 48 patients were enrolled, who had a median of 3 prior treatments. Adverse events observed were similar to those seen with Velcade. 2 patients had a CR, 20 had a PR or VGPR and 21 had stable disease. The Phase II trial is ongoing.

Dr. Jatin Shah from MD Anderson in Texas presented the results of a Phase II trial assessing ARRY-520, with or without dexamethasone. Patients enrolled had relapsed/refractory disease and had received a median of 6 previous therapies in the ARRY-520 alone arm, and 10 previous therapies in the ARRY-520 plus dexamethasone arm. Most patients had undergone previous stem cell transplantation. Grade 3 and 4 toxicities were low, there was no cumulative toxicity, and the treatment was well tolerated. Responses ranged from PR to SD, with no CR in these heavily treated patients, and 34% had progressive disease. Interestingly, responses to this agent corresponded to serum levels of alpha-1-acid glycoprotein, which can act as a marker for patients who may respond to this agent. Predose levels of alpha-1-acid glycoprotein indicated the response to ARRY-520. This was also found in the Emory study presented earlier in the day.

Dr. Sundar Jagannath from The Mount Sinai Hospital presented results of an age analysis from a Phase II trial of Pomalyst with low-dose dexamethasone in patients with relapsed/refractory multiple myeloma who have received prior therapy with Revlimid and Velcade. The results showed that patients aged 65 years or older did about as well as patients aged less than 65 years, confirming Pomalyst as an important option for elderly relapsed patients.

MMRF CoMMpassSM Study

Perhaps the pinnacle for the MMRF at this meeting was the first presentation of data from the MMRF CoMMpass study. An interim analysis of 178 patients (today we are now up to 400!), which included sequencing data on more than 30, was presented. Already, even with this preliminary data set, we are seeing brand new genomic alterations, as well as confirming others seen in our earlier Genomics Initiative and separate research initiatives. Attendees were highly engaged and were very much looking forward to the data maturing, as longitudinal data sets that integrate clinical and comprehensive (DNA and RNA sequencing) genomic data on 1,000 patients are not currently publicly available for myeloma or any cancer.

MMRF ASH Coverage

To see the full MMRF coverage from ASH with ongoing updates, please visit: www.themmrf.org/ash2013.

The MMRF Highlights From the 2013 ASH Annual Meeting Webcast/Teleconference will be held on Wednesday, December 18, at 1:00 PM ET! Hear our experts' perspectives on key myeloma clinical updates from ASH and learn about the latest advances in myeloma research and treatments. Register now by completing this form or calling 1-877-264-4949.